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LETTERS TO THE EDITOR
Atrial Fibrillation Ablation:
Role of Patient Enrollment
and Follow-Up in Clinical Results
In the August 7, 2002, issue of the Journal, Marrouche et al. (1)
reported their experience about circular mapping and ablation of
the pulmonary vein (PV) for treatment of atrial fibrillation (AF).
In group 2 (190) patients they reported, during a follow-up of 10
months, a success rate of 94% in paroxysmal AF, 90% in persistent
AF, and 80% in permanent AF. They concluded that isolation of
focal triggers initiating in PV appeared an effective cure for AF
independently from the duration of AF and left atrial site.
Pappone et al. (2), with Carto (three-dimension electroana-
tomical mapping)-assisted anatomical encircling of PV, reported
85% and 68% success rates for paroxysmal and permanent AF,
respectively. Haissaguerre et al. (3), with electrophysiologic PV
insulation (similar to Marrouche’s) reported clinical success rates of
93%, 73%, and 55% in patients with 1, 2, and 3 or more arrhythmo-
genic PV foci in paroxysmal AF (mean of 74%) and 60% in chronic
AF where left atrial size appears to be a limiting factor (4).
The reason for better results by Marrouche et al. (1) could be
found in patient enrollment and/or follow-up. Concerning enroll-
ment, was it selective or not? If the investigators enrolled only
patients in whom PV focal trigger initiated AF (documented?),
especially in paroxysmal AF, the results might not be comparable
with other studies. Moreover, in patients with coexisting atrial
flutter and AF, was PV ablation combined with right isthmus
ablation? Nabar et al. (5) demonstrated that patients who have
recurrences of both atrial flutter and AF could be cured by safer
inferior vena cava to tricuspid annulus (IVC-TA) isthmus ablation
only: they showed up to 73% success rate. Our experience (6)
confirmed that if atrial flutter is detected during infusion of 1C
antiarrhythmic drug for AF (1C atrial flutter), right isthmus
ablation is highly effective in curing AF.
The follow-up was scheduled at 1, 3, 6, and 12 months’
postablation; Holter recording was made before discharge and at 3
and 6 months. Scheduled electrocardiogram (ECG) or Holter
ECG monitoring could not be effective in detecting short-lasting
paroxysmal AF episodes, because Savelieva et al. (7) documented a
high incidence of asymptomatic AF episodes in patients with AF
treated by cardioversion. Van Noord et al. (8) in the VERDICT study
indicate that daily transtelephone ECG recording is an effective
method to detect arrhythmia recurrence in follow-up of AF patients.
We are convinced that daily transtelephone ECG recording is
effective in monitoring AF patients cured by PV isolation (elec-
trophysiologic or anatomical approach) during follow-up; because
it is expensive treatment, it could be used for three months only
(for example, from the 3rd to 15th week) and then weekly.
Finally, Marrouche et al. do not mention the incidence of left or
right atrial flutter as reported by others (3). Again, the answer may
be patient selection, because the more damaged the atrium the
more sensitive to slow conduction and reentry around anatomical
obstacle.
Thus, to avoid atrial flutter we routinely perform PV encircling
ablation with linear right (IVC-TA) and left (from mitral annulus
to low pulmonary vein) isthmus ablation with electrophysiological
validation (no-linked double potential on ablation line during
moving pacing site).
Pietro Turco, MD
Servizio di Elettrofisiologia ed Elettrostimolazione
Villa Maria Cecilia Hospital
Via Corriera 1
48010 Cotignola-RA
Italy
E-mail: pietro.turco@tin.it
Giuseppe Stabile, MD
Antonio De Simone, MD
Bilal El Jamal, MD
doi:10.1016/S0735-1097(03)00047-0
REFERENCES
1. Marrouche NF, Dresing T, Cole C, et al. Circular mapping and
ablation of the pulmonary vein for treatment of atrial fibrillation. J Am
Coll Cardiol 2002;40:464–74.
2. Pappone C, Oreto G, Rosanio S, et al. Atrial electroanatomical
remodelling after circumferential radiofrequency pulmonary vein abla-
tion. Circulation 2001;104:2539–44.
3. Haissaguerre M, Shah DC, Jais P, et al. Electrophysiological end point
for catheter ablation of atrial fibrillation initiated from multiple pulmo-
nary venous foci. Circulation 2000;101:1409–17.
4. Haissaguerre M, Jais P, Shah DC, et al. Catheter ablation of chronic
atrial fibrillation targeting the reinitiating triggers. J Cardiovasc Elec-
trophysiol 2000;11:2–10.
5. Nabar A, Rodriguez LM, Timmermans C, Van den Dool A, Smeets
JL, Wellens HJ. Effect of right atrial isthmus ablation on the occurrence
of atrial fibrillation. Observations in four patient groups having type I
atrial flutter with or without associated atrial fibrillation. Circulation
1999;99:1441–5.
6. Stabile G, De Simone A, Turco P, et al. Response to flecainide infusion
predicts long-term success of hybrid pharmacological and ablation therapy
in patients with atrial fibrillation. J Am Coll Cardiol 2001;37:1639–44.
7. Savelieva I, Camm AJ. Clinical relevance of silent atrial fibrillation:
prevalence, prognosis, quality of life, and management. J Interv Card
Electrophysiol 2000;4:369–82.
8. Van Noord T, Van Gelder IC, Tieleman RG, et al. VERDICT: the
Verapamil versus Digoxin Cardioversion Trial: a randomized study on
the role of calcium lowering for maintenance of sinus rhythm after
cardioversion of persistent atrial fibrillation. J Cardiovasc Electrophysiol
2001;12:766–9.
REPLY
We thank Dr. Turco and colleagues for the opportunity of
clarifying important issues relative to our experience with ablation
of atrial fibrillation.
The answers to most of their queries are indeed included in the
August 7, 2002, series reported in the Journal (1). Turco and
colleagues mentioned the Pappone et al. experience (2) with
CARTO-assisted encircling of the pulmonary veins (PVs). In our
laboratory we have used CARTO to isolate PVs, with poor results
and high incidence of PV stenosis (3). We showed that with
CARTO, we were able to isolate only 31% of the targeted PVs.
The overall cure rate was about 21%, with nearly 17% occurrence
of severe PV stenosis. In addition, in the CARTO cohort we
observed nearly a 20% occurrence of left atrial flutter at follow-up.
In most of the patients, left atrial flutter reflected the inability to
isolate the veins and cure atrial fibrillation (AF).
Haissaguerre et al. (4) have pioneered the circular mapping
approach. However, in their initial report the investigators most
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likely achieved isolation distal to the PV left atrial junction. As
demonstrated in our group 1 results, this approach would have limited
the long-term cure rate. In addition, we have observed that many
recurrences within the first two months’ postprocedure do not
necessarily reflect a “true” failure. The time of assessment of the
procedural success in our series could also have been partially respon-
sible for the difference in the overall cure rate after the first procedure.
We disagree strongly to the conclusion that our patient selection
criteria explain the better outcomes. Indeed, as evidence from our
population (1) shows, it is obvious that we did not exclude any patient
because of a history of AF or the presence of structural heart disease.
In our cohort, nearly 50% of these patients had persistent or
permanent AF, and about 21% had structural heart disease. Our only
selection criteria were the refractoriness to at least two antiarrhythmic
drugs and the presence of symptomatic AF.
Turco et al. also questioned our monitoring protocol postabla-
tion. However, as mentioned in our Methods section, we have
used transtelephonic monitoring in addition to the routine Holter
monitoring. Indeed, 100% of the patients reported in our series
had one month of transtelephonic monitoring, and 96% under-
went an additional month of transtelephonic monitoring during
the six months following the procedure. Analysis of daily trans-
missions in our patients showed markedly different results than
previously reported in other AF studies. As a matter of fact,
asymptomatic episodes of AF were seen only in 2 of the 430
patients who underwent PV isolation at our institution. Con-
versely, 48% of the patients recorded episodes of symptomatic
premature atrial contractions in addition to their daily transmis-
sions. These findings confirm that a highly symptomatic popula-
tion was considered for ablation in our series.
Finally, Turco and colleagues strongly advised placements of
both right and left atrial linear lesions in addition to PV isolation
or as an alternative to PV isolation. However, in our series both
right and left atrial flutters did not appear to be a relevant clinical
problem when all PVs were successfully isolated. In fact, left atrial
flutter was seen only in 3 of 430 patients post-PV isolation.
Similarly, of the 108 patients with preablation documentation of
atrial flutter/AF, only 3 required a right atrial isthmus line after
successful PV isolation (5). In contrast, in our CARTO series (3)
we reported a 20% occurrence of left atrial flutter, which reflected
an inefficient approach in isolating most of the targeted PVs.
Therefore, we do not advocate preemptive placement of linear
lesions, which seems to be important mostly when the PVs are not
effectively isolated. We do realize that ablative strategies for the
treatment of AF are rapidly evolving, and we appreciate the
importance of alternative approaches as long as they are supported
by rigorous testing.
Nassir F. Marrouche, MD
Andrea Natale, MD
Section of Pacing and Electrophysiology
Department of Cardiovascular Medicine
The Cleveland Clinic Foundation
F-15
9500 Euclid Avenue
Cleveland, Ohio 44195
E-mail: marrou@ccf.org
doi:10.1016/S0735-1097(03)00044-5
REFERENCES
1. Marrouche NF, Dresing T, Cole C, et al. Circular mapping and
ablation of the pulmonary vein for treatment of atrial fibrillation. Impact
of different catheter technologies. J Am Coll Cardiol 2002;40:464–74.
2. Pappone C, Rosanio S, Oreto G, et al. Circumferential radiofrequency
ablation of pulmonary vein ostia: a new anatomic approach for curing
atrial fibrillation. Circulation 2000;102:2619–28.
3. Kanagaratnam L, Tomassoni G, Schweikert R, et al. Empirical pulmo-
nary vein isolation in patients with chronic atrial fibrillation using a
three-dimensional nonfluoroscopic mapping system: long-term follow-
up. Pacing Clin Electrophysiol 2001;24:1774–9.
4. Haissaguerre M, Shah DC, Jais P, et al. Electrophysiological break-
throughs from the left atrium to the pulmonary veins. Circulation
2000;102:2463–5.
5. Lam C, Marrouche NF, Pavia S, et al. Successful focal atrial fibrillation
ablation prevents recurrence of atrial flutter (abstr). Pacing Clin Elec-
trophysiol 2001;24:478.
Statistical Versus Clinical Significance of the
CURE Study in Acute Coronary Syndromes
In a recent issue of JACC, Drs. Khot and Nissen focused on the
statistical versus clinical significance of the Clopidogrel in Unstable
angina to prevent Recurrent Events (CURE) study in acute
coronary syndromes (1). Several of their comments and concerns
are appropriate, but we would like to point out a number of
inaccuracies in their report.
They suggest that the CURE study (2) used a definition of
myocardial infarction (MI) that included patients with only ele-
vated serum troponin levels. In fact, the CURE definition of MI
required at least two of the following: ischemic symptoms; eleva-
tion of markers (creatine kinase-MB fraction or troponin) to at
least twice the upper limit of normal; electrocardiographic changes.
This definition is more strict than the recent European Society of
Cardiology/American College of Cardiology (ESC/ACC) consen-
sus document (3). Further evidence of a reduction in significant
MIs was a 1.2% absolute decline in the rate of subsequent Q-wave
infarctions. All MI events were adjudicated.
With respect to bleeding, it was suggested that the definition of
minor bleeding was revised between the time of ACC presentation
and its publication. In fact, no such change occurred in the
definition. The 15.3% rate of minor bleeding reported by the ACC
was an error that was corrected in the final report.
Regarding the applicability of the CURE trial to practice in the
U.S., the proportion of patients in CURE undergoing cardiac
procedures (catheterization [Cath] 44%; percutaneous coronary
intervention [PCI] 21%; coronary artery bypass graft surgery
[CABG] 16%) is very similar to other recent ACS trials (e.g.,
PURSUIT [4] [Cath 59%; PCI 24%; CABG 14%]). We agree
that clopidogrel should be stopped five days before CABG if at all
possible. With respect to the timing of surgery in U.S. practice,
more recent data from the TACTICS/TIMI-18 study (5) dem-
onstrate that the average time to cardiac surgery in the invasive arm
in the U.S. was 5.5 days. In routine clinical practice outside of a
clinical trial, it is likely that the waiting period is longer. Most
patients in the U.S. who require surgery can therefore potentially
benefit from this medication. In the small percentage of patients
who require early surgery for clinical indications, the increased risk
from bleeding on clopidogrel is only one of the issues that has to
be considered in this high-risk patient group.
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